These findings suggest that breast cancer-resistant EVs modulate immune system factors in sensitive cancer cells to evade immune detection, such as the downregulation of several MHC-related genes, including HLAs, resulting in unpaired antigen presentation. This evidence concerns the gene HLA-S and breast carcinoma.